|
Go To Contents of Reading List
1089.
Carsia RV, et al. “Adrenocortical function of the domestic
fowl: effects of orchiectomy and androgen replacement.” Proceedings of the
Society for Experimental Biology and Medicine, Volume 185, Number 2, Pages
223-232. 1987. http://www.ebmonline.org/cgi/content/abstract/185/2/223
1090.
Bowen RL et al. “An Association of Elevated Serum Gonadotropin
Concentrations and Alzheimer Disease?” Journal of Neuroendocrinology.
Volume 12, Number 4, Pages 351–354. April 2000. http://www.blackwell-synergy.com/doi/abs/10.1046/j.1365-2826.2000.00461.x
1091.
Tsai EC, et al. “Association of Bioavailable, Free, and Total
Testosterone With Insulin Resistance.” Diabetes Care. Volume 27, Number
4, Pages 861-868, 2004. http://care.diabetesjournals.org/cgi/content/abstract/27/4/861
1092.
Moorjani S, et al.
“Changes in plasma lipoproteins during various androgen suppression
therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen,
and combination treatment with luteinizing hormone-releasing hormone agonist
and flutamide.” Journal of Clinical Endocrinology & Metabolism,
Volume 66, Number 2, Pages 314-322, 1988. http://jcem.endojournals.org/cgi/content/abstract/66/2/314
1093.
Haffner SM, et al. “Decreased Sex Hormone-Binding Globulin
Predicts Noninsulin-Dependent Diabetes Mellitus in Women but not in Men.” Journal
of Clinical Endocrinology end Metabolism. Volume 77, Number 1, Pages 56-60.
1993. http://jcem.endojournals.org/cgi/reprint/77/1/56.pdf
1094.
Keating NL, et al.. “Diabetes and Cardiovascular Disease
During Androgen Deprivation Therapy for Prostate Cancer.” Journal of
Clinical Oncology. Volume 24, Number 27, Pages 4448-56. September 20, 2006. http://jco.ascopubs.org/cgi/reprint/24/27/4448
1095.
De Coster R, et al. “Effects of high-dose ketoconazole and
dexamethasone on ACTH-stimulated adrenal steroidogenesis in orchiectomized
prostatic cancer patients..” Acta Endocrinologica. (Copenhagen) Volume115,
Number 2, Pages 265-71. June 1987. http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&list_uids=3037835&cmd=Retrieve&indexed=google
1096.
Barrett-Connor E, et al. “Endogenous Sex Hormone Levels In
Older Adult Men With Diabetes Mellitus.” American Journal of Epidemiology.
Volume 132, Number 5, Pages 895-901. 1990. http://aje.oxfordjournals.org/cgi/content/abstract/132/5/895
1097.
Golden SH, et al. “Endogenous Sex Hormones and Glucose
Tolerance Status in Postmenopausal Women.” Journal of Clinical Endocrinology
& Metabolism. Volume
92,
Number 4, Pages 1289-1295. 2007. http://jcem.endojournals.org/cgi/content/abstract/92/4/1289
1098.
Moorjani S, et al. “Changes in plasma lipoproteins during
various androgen suppression therapies in men with prostatic carcinoma: effects
of orchiectomy, estrogen, and combination treatment with luteinizing
hormone-releasing hormone agonist and flutamide.” Journal of Clinical
Endocrinology & Metabolism, Volume 66, Number 2, Pages 314-322, 1988. http://jcem.endojournals.org/cgi/content/abstract/66/2/314
1099.
Bruschi F, et al. “Lipoprotein(a) and other lipids after
oophorectomy and estrogen replacement therapy.” Obstetrics & Gynecology.
Volume 88, Number 6, Pages 950-954. 1996. http://www.greenjournal.org/cgi/content/abstract/88/6/950
1100.
Paoletti AM, et al. “Low androgenization index in elderly
women and elderly men with Alzheimer's disease..” Neurology.
Volume 62,
Number 2, Pages 301-3. Jan 27, 2004. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=pubmed&dopt=AbstractPlus&list_uids=14745075
1101.
Liu T, et al. “Luteinizing hormone receptor mediates neuronal
pregnenolone production via up-regulation of steroidogenic acute regulatory
protein expression.” Journal of Neurochemistry. Volume 100,
Number 5,
Pages 1329–1339. March 2007. http://www.blackwell-synergy.com/doi/abs/10.1111/j.1471-4159.2006.04307.x
1102.
Pennanen C, et al. “Serum Testosterone Levels in Makes with
Alzheimer’s Disease.” Journal of Neuroendocrinology. Volume 16, Issue
2,
Pages 95-98. 2004, http://www.blackwell-synergy.com/doi/abs/10.1111/j.0953-8194.2004.01133.x
1103.
Liu E, et al.. “Sex Differences of Endogenous Sex Hormones and
Risk of Type 2 Diabetes.” Journal of American Medical Association.
Volume 295, Number 11, Pages 1288-1299. March 15, 2006. http://jama.ama-assn.org/cgi/reprint/295/11/1288
1104.
Kalme T. et al. “Sex Hormone-Binding Globulin and Insulin-Like
Growth Factor-Binding Protein-1 as Indicators of Metabolic Syndrome,
Cardiovascular Risk, and Mortality in Elderly Men.” Journal of Clinical
Endocrinology & Metabolism Volume 90, Number 3, Pages 1550–1556.
2005. http://jcem.endojournals.org/cgi/content/short/90/3/1550
1105.
Sutton-Tyrrell K, et al. “Sex Hormone–Binding Globulin and the
Free Androgen Index Are Related to Cardiovascular Risk Factors in Multiethnic
Premenopausal and Perimenopausal Women Enrolled in the Study of Women Across
the Nation (SWAN).” Circulation. Volume 111, Number 10, Pages 1242-1249.
2005. http://circ.ahajournals.org/cgi/content/full/111/10/1242
1106.
Da Silva JAP. “Sex hormones, glucocorticoids and autoimmunity:
facts and hypotheses.” Annals of the Rheumatic Diseases. Volume 54,
Pages 6-16. 1995. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=7880125
1107.
Ohnemus U, et al. “The Hair Follicle as an Estrogen Target and
Source.” Endocrine Reviews. Volume 27, Number 6, Pages 677–706. 2006.
http://edrv.endojournals.org/cgi/reprint/27/6/677
1108.
Smith MR, et al. “Changes in Body Composition during Androgen
Deprivation Therapy for Prostate Cancer.” The Journal of Clinical
Endocrinology & Metabolism. Volume 87, Number 2, Pages 599-603.
2002. http://jcem.endojournals.org/cgi/reprint/87/2/599
1109.
Inaba M, et al. “Marked hyperglycemia after
androgen-deprivation therapy for prostate cancer and usefulness of pioglitazone
for its treatment.” Metabolism. Volume 54, Number 1, Pages 55-9,
January
2005. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15562380&dopt=Abstract
1110.
Dennis LK, et al. “Meta-Analysis of Measures of Sexual
Activity and Prostate Cancer.” Epidemiology. Volume 13, Number 1, Pages
72-79, January 2002. http://www.epidem.com/pt/re/epidemiology/userLogin.htm;jsessionid=H14WrRLmrYVP7S9Rv9GCSCylK4cl1LRn15K6TtVJ3kQ2NsT0d5gq!1390229169!181195629!8091!-1
1111.
Braga-Basaria M, et al. “Metabolic Syndrome in Men With
Prostate Cancer Undergoing Long-Term Androgen-Deprivation Therapy.” Journal
of Clinical Oncology. Volume 24, Number 24, Pages 3979-398. August 20,
2006. http://jco.ascopubs.org/cgi/content/abstract/24/24/3979
1112.
Smith MR. “Obesity
and Sex Steroids during Gonadotropin-Releasing Hormone Agonist Treatment for
Prostate Cancer.” Clinical Cancer Research. Volume 13, Pages
241-245,
January 1, 2007. http://clincancerres.aacrjournals.org/cgi/content/abstract/13/1/241
1113.
Shumaker SA, et al. “Estrogen Plus Progestin and the Incidence
of Dementia and Mild Cognitive Impairment in Postmenopausal Women.” Journal
of American Medical Association. Volume 289, Number 20, 2651-2662. May 28,
2003. http://jama.ama-assn.org/cgi/reprint/289/20/2651
1114.
Shumaker SA, et al. “Conjugated Equine Estrogen and the
Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women.” Journal
of American Medical Association. Volume 291, Number 24, Pages 2947-2958.
June 23/30, 2004. http://jama.ama-assn.org/cgi/content/abstract/291/24/2947
1115.
Schneider LS. “Estrogen and Dementia.” Journal of American
Medical Association. Volume 291, Number 24, Pages 3005-3007. 2004. http://jama.ama-assn.org/cgi/content/extract/291/24/3005
or, http://www.obgyn.net/newsheadlines/womens_health-Dementia-20040726-17.asp
1116.
Rocca WA, et al. “Increased risk of cognitive
impairment or dementia in women who underwent oophorectomy before menopause.” Neurology.
Published online before print August 29, 2007. http://www.neurology.org/cgi/content/abstract/01.wnl.0000276984.19542.e6v1
1117.
Hull RL, et al. “Oophorectomy Promotes Islet Amyloid
Formation in Human Islet Amyloid Polypeptide Transgenic Mice.” DIABETES,
Volume 50, Supplement 1, Pages S184-S185.
February 2001. http://diabetes.diabetesjournals.org/cgi/reprint/50/suppl_1/S184.pdf
1118.
Webber KM, et al. “The Future of Hormone Therapy: What Basic
Science and Clinical Studies Teach Us: Estrogen Bows to a New Master: The Role
of Gonadotropins in Alzheimer Pathogenesis.” Annals of the New York Academy
of Sciences. Volume 1052, Number 1, Pages 201–209. June 2005. http://www.blackwell-synergy.com/doi/abs/10.1196/annals.1347.020
1119.
Beer TM, et al. “Testosterone Loss and Estradiol
Administration Modify Memory in Men.” Journal of Urology. Volume 175,
Pages130-135, January 2006. http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B7XMT-4HSRD7N-1F&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=8fc9400a8b3cb236220d1296c8dea0b5
1120.
Purnell JQ, et al. “Effects of transdermal estrogen on levels
of lipids, lipase activity, and inflammatory markers in men with prostate
cancer.” Journal of Lipid Research. Volume 47, Pages 349-355. 2006.
http://www.jlr.org/cgi/reprint/47/2/349
1121.
Basaria S, et al. “Hyperglycemia and Insulin Resistance in Men
with Prostate Carcinoma who Receive Androgen- Deprivation Therapy.” Cancer.
Volume106, Number 3, Pages 581–8. 2006. http://www3.interscience.wiley.com/cgi-bin/abstract/112223505/ABSTRACT?CRETRY=1&SRETRY=0
1122.
Alibhai SMH, et al. “Long-term side effects of androgen
deprivation therapy in men with non-metastatic prostate cancer: A systematic
literature review.” Critical Reviews in Oncology/Hematology. Volume 60,
Issue 3, Pages 201–215. December 2006. http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T5S-4KGG5XT-4&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=1500e579459cff7b15ab8e1ec751a332
1123.
Almeida OP, et al. “One year follow-up study of the
association between chemical castration, sex hormones, beta-amyloid, memory and
depression in men.” Psychoneuroendocrinology. Volume 29, Issue
8, Pages
1071–1081. September 2004. http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6TBX-4BG3J4P-1&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=c58f2afa90a5f102cc970a3adf0fcc35
1124.
Shahinian VB, et al. “Risk of Fracture after Androgen
Deprivation for Prostate Cancer.” New England Journal of Medicine,
Volume 352, Number 2, Pages 154–164. January 13, 2005. http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=1920183&blobtype=pdf
1125.
Almeida OP and Flicker L. “Testosterone and dementia: too
much ado about too little data.” Journal of the British Menopause Society,
Volume 9, Number 3, Pages 107-110, September 2003. http://www.ingentaconnect.com/content/rsm/jbms/2003/00000009/00000003/art00006
1126.
Famili P, et al. “The Effect of Androgen Deprivation Therapy
on Periodontal Disease in Men With Prostate Cancer.” Journal of Urology. Volume 177, Number 3, Pages
921–924. March 2007. . http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=1934505&blobtype=pdf
1127.
Melton LJ 3rd, et al. “Fracture
risk following
bilateral orchiectomy.” Journal of Urology. Volume 169, Number 5, Pages
1747-50. May 2003. http://www.ncbi.nlm.nih.gov/pubmed/12686824?dopt=Abstract
1128.
Smith MR, et al. “Changes in Body Composition during Androgen
Deprivation Therapy for Prostate Cancer.” Journal of Clinical Endocrinology
& Metabolism. Volume 87, Number 2, Pages 599-603. 2002. http://jcem.endojournals.org/cgi/reprint/87/2/599
1129.
Braga-Basaria M, et al. “Metabolic Syndrome in Men With
Prostate Cancer Undergoing Long-Term Androgen-Deprivation Therapy.” Journal
of Clinical Oncology. Volume 24, Number 24, Pages 3979-3983. August 20,
2006. http://jco.ascopubs.org/cgi/reprint/24/24/3979
1130.
Smith MR. “Obesity and Sex Steroids during Gonadotropin-Releasing
Hormone Agonist Treatment for Prostate Cancer.” Clinical Cancer Research.
Volume 13, Pages 241-245, January 1, 2007. http://clincancerres.aacrjournals.org/cgi/reprint/13/1/241
Go To Contents of Reading List
|
Enter content here  |
|
Enter content here |
Enter supporting content here